利用群体药动学模型改善危重患儿头孢唑林暴露
该单中心观察性研究纳入58例18岁以下危重患儿,比较常规给药与模型指导给药后头孢唑林暴露。模型指导给药组达到最佳暴露比例更高(79% vs 44%,P=.01),暴露不足更少(10% vs 46%,P=.008),且未增加过度暴露;模型组C反应蛋白下降50%时间更短(3 vs 4天,P=.045)。
要点
- 模型指导给药可提高危重患儿头孢唑林最佳暴露比例(79% vs 44%)。
- 模型指导给药减少暴露不足(10% vs 46%),未增加过度暴露。
- 模型组C反应蛋白下降50%时间更短,但临床获益需进一步研究。
核心结论
- 使用个体化头孢唑林模型指导给药可改善危重患儿的药物暴露。
- 头孢唑林药动学模型应用的临床获益尚需进一步研究评估。
研究设计与样本
- 单中心观察性研究,纳入58例18岁以下危重患儿,其中39例接受常规给药、19例接受模型指导给药。
- 分析每个头孢唑林疗程稳态时首次血药浓度,比较两组暴露情况。
主要发现
- 模型指导给药组最佳暴露比例高于常规组(79% vs 44%,P=.01)。
- 模型指导给药组暴露不足比例低于常规组(10% vs 46%,P=.008)。
- 两组过度暴露比例无显著差异(11% vs 10%,P=1)。
- 模型组C反应蛋白下降50%的时间短于常规组(3天 vs 4天,P=.045)。
关键数值与推荐
- 最佳暴露定义为:游离浓度超过4倍最低抑菌浓度(MIC)并维持100%给药间隔,且总谷浓度或平台浓度低于100 mg·L-1。
- 模型指导给药组连续输注比例高于常规组(100% vs 59%)。
临床怎么用
- 对危重患儿使用头孢唑林时,可考虑采用群体药动学模型指导个体化给药以提高暴露达标率。
- 模型指导给药有助于减少暴露不足,且未增加过度暴露风险。
局限性
- 单中心观察性研究,样本量较小(58例),结果需外推验证。
- 模型指导给药组连续输注比例更高,可能混杂给药方式的影响。
- 临床获益(如感染治愈率)未在本研究中评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Population pharmacokinetics (PK) models may be effective in improving antibiotic exposure with individualized dosing. The aim of the study is to assess cefazolin exposure using a population PK model in critically ill children. METHODS: We conducted a single-centre observational study including children under 18 years old who had cefazolin plasma monitoring before and after a cefazolin model implementation. The first concentration at steady state of each cefazolin course was analysed. The optimal exposure was defined by concentration values ranging from free concentration over four times the minimal inhibitory concentration (MIC) for 100% of the dosing interval to total trough or plateau concentration under 100 mg. L-1. RESULTS: A total of 58 patients were included, of whom 39 and 19 children received conventional dosing or model-informed dosing, respectively. Median [range] age was 2.3 [0.1-17] years old, and median weight was 14.2 [2.9-72] kg. There were more continuous infusions (CI) in the model group than in the conventional group (n = 19/19 [100%] vs. n = 23/39 [59%]). Compared to conventional dosing, model-informed dosing provided more optimal exposure (n = 17/39 [44%] vs. n = 15/19 [79%], P = .01) and less underexposure (n = 18/39 [46%] vs. n = 2/19 [10%], P = .008), without increasing overexposure (n = 4/39 [10%] vs. n = 2/19 [11%], P = 1). Moreover, the time to C-reactive protein decrease by 50% was significantly shorter in the model group than the conventional group (3 [0.5-13] vs. 4 [1-34]; P = .045). CONCLUSIONS: Use of individualized cefazolin model-informed dosing improves critically ill children's exposure. Further studies are needed to assess the clinical benefit of cefazolin PK model application.
引用
- Rivaud C, Oualha M, Salvador E, et al. Improving cefazolin exposure in critically ill children using a population pharmacokinetic model. Br J Clin Pharmacol. 2024. PMID: 39209527. doi:10.1111/bcp.16224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。